JWH-198

From Wikipedia, the free encyclopedia
Jump to: navigation, search
JWH-198
JWH-198 structure.png
Systematic (IUPAC) name
(1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-ylmethanone
Clinical data
Legal status ?
Identifiers
CAS number 166599-76-4 N
ATC code ?
PubChem CID 10319620
ChemSpider 8495084 N
Chemical data
Formula C26H26N2O3 
Mol. mass 414.495 g/mol
 N (what is this?)  (verify)

JWH-198 is a drug from the aminoalkylindole family which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-198 has a binding affinity at the CB1 receptor of 10nM, binding around four times more tightly than the parent compound JWH-200, which has no substitution on the naphthoyl ring.[1] It has been used mainly in molecular modelling of the cannabinoid receptors.[2][3]

See also[edit]

References[edit]

  1. ^ Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. Current Medicinal Chemistry, 2005; 12: 1395-1411.
  2. ^ Eissenstat MA, et al. (August 1995). "Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics". Journal of Medicinal Chemistry 38 (16): 3094–105. doi:10.1021/jm00016a013. PMID 7636873. 
  3. ^ Shim JY, et al. (November 1998). "Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis". Journal of Medicinal Chemistry 41 (23): 4521–32. doi:10.1021/jm980305c. PMID 9804691.